Roche Secures Global Rights to Hanmi’s Muscle-Sparing Obesity Drug in $2.3B Deal
Roche’s Genentech unit has agreed to pay up to $2.3 billion for global rights to HM17321, a clinical-stage obesity drug from South Korea’s Hanmi Pharm. The deal includes a $190 million upfront payment and targets a non-incretin mechanism that aims to reduce weight while preserving muscle mass, a key limitation of current GLP-1 therapies.